Characterization of high-purity, double virus inactivated and stable plasma-derived anti-haemophilic clotting factor-VIII/vWF complex

SummaryAllogenic proteins that contaminate intermediate purity clotting factor concentrates may activate the immune system of HIV-infected haemophilic patients. In 37 haemophilic patients infected with HIV who had originally been treated with intermediate purity factor VIII concentrate and then changed to monoclonally-purified high purity factor VIII concentrate the rates of CD4+ decline (109/1 per year) were 0.06 before and 0.02 after a switch to high purity products (p = 0.01). The median follow-up of patients after the switch to high purity products was 1.7 years (range 0.2 to 3 years). This significant change in the rate of CD4 decline was independent of the starting CD4 count, age and antiretroviral therapy. This result is consistent with those from randomised trials of the introduction of high-purity concentrate. Given the strong association between the CD4+ count and survival, treatment with high purity rather than intermediate purity clotting factor concentrate may confer a survival benefit for HIV-infected haemophilic patients.

Download Full-text

Recombinant clotting factor VIII concentrates: Heterogeneity and high-purity evaluation

PROTEOMICS - CLINICAL APPLICATIONS ◽

10.1002/prca.201090095 ◽

2010 ◽

Vol 4 (10-11) ◽

pp. 878-878

Author(s):

Gian Maria D'Amici ◽

Anna Maria Timperio ◽

Federica Gevi ◽

Giuliano Grazzini ◽

Lello Zolla

Keyword(s):

Factor Viii ◽

High Purity ◽

Clotting Factor ◽

Factor Viii Concentrates ◽

Purity Evaluation

Download Full-text

In vitro and in vivo characterization of a high-purity, solvent/detergent-treated factor VIII concentrate: Evidence for its therapeutic efficacy in von Willebrand's disease

European Journal Of Haematology ◽

10.1111/j.1600-0609.1989.tb01244.x ◽

2009 ◽

Vol 43 (1) ◽

pp. 7-14 ◽

Cited By ~ 16

Author(s):

Claudine Mazurier ◽

Christophe Romeuf ◽

Armelle Parquet-Gernez ◽

Maurice Goudemand

Keyword(s):

Factor Viii ◽

High Purity ◽

Therapeutic Efficacy ◽

Von Willebrand's Disease ◽

Von Willebrand’S Disease ◽

In Vivo Characterization

Download Full-text

TEM characterization of WSix films

Proceedings, annual meeting, Electron Microscopy Society of America ◽

10.1017/s0424820100171973 ◽

1994 ◽

Vol 52 ◽

pp. 848-849

Author(s):

V. C. Kannan ◽

S. M. Merchant ◽

R. B. Irwin ◽

A. K. Nanda ◽

M. Sundahl ◽

...

Keyword(s):

Integrated Circuits ◽

Vapor Deposition ◽

High Purity ◽

Physical Vapor Deposition ◽

Thermal Treatments ◽

Rapid Thermal Anneal ◽

Tungsten Silicide ◽

Tem Characterization ◽

Metal Silicides

Metal silicides such as WSi2, MoSi2, TiSi2, TaSi2 and CoSi2 have received wide attention in recent years for semiconductor applications in integrated circuits. In this study, we describe the microstructures of WSix films deposited on SiO2 (oxide) and polysilicon (poly) surfaces on Si wafers afterdeposition and rapid thermal anneal (RTA) at several temperatures. The stoichiometry of WSix films was confirmed by Rutherford Backscattering Spectroscopy (RBS). A correlation between the observed microstructure and measured sheet resistance of the films was also obtained.WSix films were deposited by physical vapor deposition (PVD) using magnetron sputteringin a Varian 3180. A high purity tungsten silicide target with a Si:W ratio of 2.85 was used. Films deposited on oxide or poly substrates gave rise to a Si:W ratio of 2.65 as observed by RBS. To simulatethe thermal treatments of subsequent processing procedures, wafers with tungsten silicide films were subjected to RTA (AG Associates Heatpulse 4108) in a N2 ambient for 60 seconds at temperatures ranging from 700° to 1000°C.

Download Full-text

Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients

Haemophilia ◽

10.1046/j.1365-2516.1999.00282.x ◽

1999 ◽

Vol 5 (2) ◽

pp. 88 ◽

Cited By ~ 2

Author(s):

STEVEN R. DEITCHER

Keyword(s):

Factor Viii ◽

Von Willebrand Factor ◽

High Purity ◽

Haemophilia A ◽

Severe Haemophilia ◽

Factor Viii Concentrates ◽

Von Willebrand ◽

Willebrand Factor

Download Full-text

Antibody to Hepatitis G Mrus after a Vapour-Heated Factor Vlll Goncentrate

Thrombosis and Haemostasis ◽

10.1055/s-0038-1647291 ◽

1990 ◽

Vol 64 (02) ◽

pp. 232-234 ◽

Cited By ~ 21

Author(s):

P M Mannucci ◽

A R Zanetti ◽

M Colombo ◽

A Chistolini ◽

R De Biasi ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Hepatitis B ◽

Factor Viii ◽

Alanine Aminotransferase ◽

Household Contact ◽

Clotting Factor ◽

Double Infection ◽

Marked Elevation ◽

Clotting Factor Concentrates

SummaryTo evaluate whether or not clotting factor concentrates exposed to virucidal procedures transmitted hepatitis C, sera obtained in 1984–1986 from 27 previously untreated hemophiliacs infused with a vapour-heated factor VIII concentrate were tested retrospectively for the antibody to the hepatitis C virus (anti- HCV). A 2-year-old hemophiliac, negative for anti-HCV before administration of concentrate, seroconverted at week 12 and remained anti-HCV positive thereafter. Both his parents were anti-HCV negative and he had no other household contact. The patient had also become HBsAg positive at week 8 and had at the same time a marked elevation of alanine aminotransferase. His double infection with the hepatitis B and C viruses indicates that hot vapour was not completely effective in inactivating these viruses.

Download Full-text

Factor VIII Concentrate: What is “High Purity”?

Thrombosis and Haemostasis ◽

10.1055/s-0038-1648895 ◽

1994 ◽

Vol 72 (03) ◽

pp. 483-484 ◽

Cited By ~ 1

Author(s):

Axel Schoppmann ◽

Alfred Weber ◽

Felix Hondl ◽

Yendra Linnau

Keyword(s):

Factor Viii ◽

High Purity

Download Full-text